These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12374881)

  • 1. Adrenergic-receptor polymorphisms and heart failure.
    Hajjar RJ; MacRae CA
    N Engl J Med; 2002 Oct; 347(15):1196-9. PubMed ID: 12374881
    [No Abstract]   [Full Text] [Related]  

  • 2. Polymorphisms of adrenergic receptors and the risk of heart failure.
    Little J; Gwinn M; Khoury M
    N Engl J Med; 2003 Jan; 348(5):468-70; author reply 468-70. PubMed ID: 12557865
    [No Abstract]   [Full Text] [Related]  

  • 3. Polymorphisms of adrenergic receptors and the risk of heart failure.
    Maitland ML; Gomberg-Maitland M
    N Engl J Med; 2003 Jan; 348(5):468-70; author reply 468-70. PubMed ID: 12557866
    [No Abstract]   [Full Text] [Related]  

  • 4. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure.
    Small KM; Wagoner LE; Levin AM; Kardia SL; Liggett SB
    N Engl J Med; 2002 Oct; 347(15):1135-42. PubMed ID: 12374873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms of adrenergic receptors and the risk of heart failure.
    Meisel C; Köpke K; Roots I
    N Engl J Med; 2003 Jan; 348(5):468-70; author reply 468-70. PubMed ID: 12556550
    [No Abstract]   [Full Text] [Related]  

  • 6. β1- and α2C-adrenergic receptor polymorphisms and the antiarrhythmic effect of bucindolol in heart failure with reduced ejection fraction.
    Lymperopoulos A; Negussie S; Walklett K
    Pharmacogenomics; 2013 Oct; 14(13):1545-9. PubMed ID: 24088125
    [No Abstract]   [Full Text] [Related]  

  • 7. Alpha2cDel322-325 and beta1Arg389 adrenergic polymorphisms are not associated with reduced left ventricular ejection fraction or increased left ventricular volume.
    Canham RM; Das SR; Leonard D; Abdullah SM; Mehta SK; Chung AK; Li JL; Victor RG; Auchus RJ; Drazner MH
    J Am Coll Cardiol; 2007 Jan; 49(2):274-6. PubMed ID: 17222742
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacogenomics and the failing heart are we waiting for godot?
    Mann DL; McNamara DM
    J Am Coll Cardiol; 2008 Aug; 52(8):652-4. PubMed ID: 18702969
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of beta1- and alpha2c-adrenergic receptor polymorphisms and their combination in heart failure: a case-control study.
    Metra M; Zani C; Covolo L; Nodari S; Pezzali N; Gelatti U; Donato F; Nardi G; Dei Cas L
    Eur J Heart Fail; 2006 Mar; 8(2):131-5. PubMed ID: 16188498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.
    Lobmeyer MT; Gong Y; Terra SG; Beitelshees AL; Langaee TY; Pauly DF; Schofield RS; Hamilton KK; Herbert Patterson J; Adams KF; Hill JA; Aranda JM; Johnson JA
    Pharmacogenet Genomics; 2007 Apr; 17(4):277-82. PubMed ID: 17496726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple interactions between the alpha 2C- and beta1-adrenergic receptors influence heart failure survival.
    Kardia SL; Kelly RJ; Keddache MA; Aronow BJ; Grabowski GA; Hahn HS; Case KL; Wagoner LE; Dorn GW; Liggett SB
    BMC Med Genet; 2008 Oct; 9():93. PubMed ID: 18947427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure.
    Aleong RG; Sauer WH; Robertson AD; Liggett SB; Bristow MR
    Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):137-43. PubMed ID: 23275278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms.
    O'Connor CM; Fiuzat M; Carson PE; Anand IS; Plehn JF; Gottlieb SS; Silver MA; Lindenfeld J; Miller AB; White M; Walsh R; Nelson P; Medway A; Davis G; Robertson AD; Port JD; Carr J; Murphy GA; Lazzeroni LC; Abraham WT; Liggett SB; Bristow MR
    PLoS One; 2012; 7(10):e44324. PubMed ID: 23071495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure.
    Bristow MR; Murphy GA; Krause-Steinrauf H; Anderson JL; Carlquist JF; Thaneemit-Chen S; Krishnan V; Abraham WT; Lowes BD; Port JD; Davis GW; Lazzeroni LC; Robertson AD; Lavori PW; Liggett SB
    Circ Heart Fail; 2010 Jan; 3(1):21-8. PubMed ID: 19880803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose Response of β-Blockers in Adrenergic Receptor Polymorphism Genotypes.
    Parikh KS; Fiuzat M; Davis G; Neely M; Blain-Nelson P; Whellan DJ; Abraham WT; Adams KF; Felker GM; Liggett SB; O'Connor CM; Bristow MR
    Circ Genom Precis Med; 2018 Aug; 11(8):e002210. PubMed ID: 30354340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No positive association between adrenergic receptor variants of alpha2cDel322-325, beta1Ser49, beta1Arg389 and the risk for heart failure in the Japanese population.
    Nonen S; Okamoto H; Akino M; Matsui Y; Fujio Y; Yoshiyama M; Takemoto Y; Yoshikawa J; Azuma J; Kitabatake A
    Br J Clin Pharmacol; 2005 Oct; 60(4):414-7. PubMed ID: 16187973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomics of beta1-adrenergic receptor polymorphisms in heart failure.
    Liggett SB
    Heart Fail Clin; 2010 Jan; 6(1):27-33. PubMed ID: 19945058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms of adrenoceptors are not associated with an increased risk of adverse event in heart failure: a MERIT-HF substudy.
    Savva J; Maqbool A; White HL; Galloway SL; Yuldasheva NY; Ball SG; West RM; De Boer RA; Van Veldhuisen DJ; Balmforth AJ;
    J Card Fail; 2009 Jun; 15(5):435-41. PubMed ID: 19477404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac function in genetically engineered mice with altered adrenergic receptor signaling.
    Rockman HA; Koch WJ; Lefkowitz RJ
    Am J Physiol; 1997 Apr; 272(4 Pt 2):H1553-9. PubMed ID: 9139936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol.
    Sehnert AJ; Daniels SE; Elashoff M; Wingrove JA; Burrow CR; Horne B; Muhlestein JB; Donahue M; Liggett SB; Anderson JL; Kraus WE
    J Am Coll Cardiol; 2008 Aug; 52(8):644-51. PubMed ID: 18702968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.